Spero Therapeutics's book value per share for the quarter that ended in Dec. 2023 was $2.02.
During the past 12 months, Spero Therapeutics's average Book Value Per Share Growth Rate was 39.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -23.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -23.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Spero Therapeutics was -8.50% per year. The lowest was -28.00% per year. And the median was -24.75% per year.
During the past 9 years, the highest P/B Ratio of Spero Therapeutics was 6.30. The lowest was 0.49. And the median was 2.12.
Good Sign:
Spero Therapeutics Inc stock PB Ratio (=0.72) is close to 1-year low of 0.68
Spero Therapeutics Book Value per Share Historical Data
The historical data trend for Spero Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Spero Therapeutics's Book Value per Share
For the Biotechnology subindustry, Spero Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's PB Ratio falls into.
Spero Therapeutics Book Value per Share Calculation
Spero Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Spero Therapeutics (NAS:SPRO) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Spero Therapeutics Book Value per Share Related Terms
Thank you for viewing the detailed overview of Spero Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Spero Therapeutics (Spero Therapeutics) Business Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SPRO has been successfully added to your 